Danish pharmaceutical company Novo Nordisk on Friday (12 December) announced the launch of its blockbuster anti–type 2 diabetes drug Ozempic (semaglutide injection) in India, with an entry price of Rs 2,200 per week for the 0.25 mg dosage.

The drug is available in three dosage strengths — 0.25 mg, 0.5 mg and 1 mg — in single-use, pre-filled pens fitted with Novofine needles designed for painless subcutaneous injections.

Also Read : Centre drafts new law to tighten drug and medical device regulation

The company has adopted market-specific pricing for the once-weekly injectable with the 0.5 mg dose is priced at Rs 2,542 per week, while the 1 mg maintenance dose will cost Rs 2,793 per week.

Novo Nordish launches Ozempic in India

Vikrant Shrotriya, managing director of Novo Nordisk Indi

See Full Page